Astrazeneca (AZN) Other Non-Current Assets (2017 - 2025)
Astrazeneca has reported Other Non-Current Assets over the past 9 years, most recently at $559.0 million for Q4 2025.
- Quarterly results put Other Non-Current Assets at $559.0 million for Q4 2025, up 57.02% from a year ago — trailing twelve months through Dec 2025 was $559.0 million (up 57.02% YoY), and the annual figure for FY2025 was $559.0 million, up 57.02%.
- Other Non-Current Assets for Q4 2025 was $559.0 million at Astrazeneca, up from $356.0 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for AZN hit a ceiling of $559.0 million in Q4 2025 and a floor of $243.0 million in Q4 2022.
- Median Other Non-Current Assets over the past 5 years was $356.0 million (2024), compared with a mean of $364.6 million.
- Biggest five-year swings in Other Non-Current Assets: plummeted 37.85% in 2022 and later soared 57.02% in 2025.
- Astrazeneca's Other Non-Current Assets stood at $391.0 million in 2021, then crashed by 37.85% to $243.0 million in 2022, then increased by 12.76% to $274.0 million in 2023, then increased by 29.93% to $356.0 million in 2024, then soared by 57.02% to $559.0 million in 2025.
- The last three reported values for Other Non-Current Assets were $559.0 million (Q4 2025), $356.0 million (Q4 2024), and $274.0 million (Q4 2023) per Business Quant data.